Literature DB >> 23275203

Distribution and phenotypic expression of mineralocorticoid receptor and CYP11B2 T-344C polymorphisms in a Taiwanese hypertensive population.

Sung-Kien Sia1, Hui-Ling Chiou, Shiuan-Chih Chen, Chin-Feng Tsai, Shun-Fa Yang, Kwo-Chang Ueng.   

Abstract

Numerous genetic loci are involved in the pathogenesis of hypertension, including genes related to aldosterone synthesis and mineralocorticoid receptor. The aim of this study was to evaluate the genotypic distribution of mineralocorticoid receptor and cytochrome P450 11B2 (CYP11B2) T-344C polymorphisms and their relationship with hypertension and cardiac remodeling in a Taiwanese population. Genomic DNA extracted from peripheral blood samples was subjected to polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis for the mineralocorticoid receptor loci, G3514C and A4582C, and CYP11B2 T-344C. The genetic distribution and the association with echocardiographic measurements were analyzed. A total of 192 normotensive and 514 hypertensive Taiwanese patients were recruited. Statistical analysis revealed no significant differences in the genetic distribution of mineralocorticoid receptor and CYP11B2 polymorphisms between normotensive and hypertensive patients, nor were there differences in the echocardiographic measurements. Female patients with the T/T genotype of CYP11B2 were more likely to have hypertension (p = 0.045), compared with the T/C or C/C genotypes. In addition, female hypertensive patients carrying C-allele had significantly greater left ventricular mass (p = 0.0215) and left atrial dimension (p = 0.0081). Such differences were not observed in the male patients. Our data suggest that CYP11B2 T-344C polymorphism affects left ventricular structures only in the female hypertensive population. This gender-difference needs to be further elucidated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23275203     DOI: 10.1007/s11033-012-2446-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  20 in total

1.  Aldosterone is produced from ventricles in patients with essential hypertension.

Authors:  Nobuyasu Yamamoto; Hirofumi Yasue; Yuji Mizuno; Michihiro Yoshimura; Hiromi Fujii; Masafumi Nakayama; Eisaku Harada; Shota Nakamura; Teruhiko Ito; Hisao Ogawa
Journal:  Hypertension       Date:  2002-05       Impact factor: 10.190

Review 2.  Aldosterone-receptor antagonism in hypertension.

Authors:  Pieter M Jansen; A H Jan Danser; Ben P Imholz; Anton H van den Meiracker
Journal:  J Hypertens       Date:  2009-04       Impact factor: 4.844

3.  Genetic polymorphism of CYP11B2 gene and hypertension in Japanese.

Authors:  S Tamaki; N Iwai; Y Tsujita; M Kinoshita
Journal:  Hypertension       Date:  1999-01       Impact factor: 10.190

4.  Analysis of renin-angiotensin-aldosterone system gene polymorphisms in resistant hypertension.

Authors:  S R S Freitas; P H Cabello; R S Moura-Neto; L C Dolinsky; A B Lima; M Barros; I Bittencourt; I L Cordovil
Journal:  Braz J Med Biol Res       Date:  2007-03       Impact factor: 2.590

5.  Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension.

Authors:  K Tsukada; T Ishimitsu; M Teranishi; M Saitoh; M Yoshii; H Inada; S Ohta; M Akashi; J Minami; H Ono; M Ohrui; H Matsuoka
Journal:  J Hum Hypertens       Date:  2002-11       Impact factor: 3.012

6.  Contrasting associations between aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites.

Authors:  Haidong Zhu; Giuseppe A Sagnella; Yanbin Dong; Michelle A Miller; Abiodun Onipinla; Nirmala D Markandu; Graham A MacGregor
Journal:  J Hypertens       Date:  2003-01       Impact factor: 4.844

7.  Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart.

Authors:  M Lombès; N Alfaidy; E Eugene; A Lessana; N Farman; J P Bonvalet
Journal:  Circulation       Date:  1995-07-15       Impact factor: 29.690

Review 8.  Role of the C-344T aldosterone synthase gene variant in left ventricular mass and left ventricular structure-related phenotypes.

Authors:  S Sookoian; T F Gianotti; C J Pirola
Journal:  Heart       Date:  2007-08-13       Impact factor: 5.994

9.  Interaction between the C(-344)T polymorphism of CYP11B2 and age in the regulation of blood pressure and plasma aldosterone levels: cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study.

Authors:  Paola Russo; Alfonso Siani; Antonella Venezia; Roberto Iacone; Ornella Russo; Gianvincenzo Barba; Lanfranco D'Elia; Francesco P Cappuccio; Pasquale Strazzullo
Journal:  J Hypertens       Date:  2002-09       Impact factor: 4.844

Review 10.  Echocardiography-based left ventricular mass estimation. How should we define hypertrophy?

Authors:  Murilo Foppa; Bruce B Duncan; Luis E P Rohde
Journal:  Cardiovasc Ultrasound       Date:  2005-06-17       Impact factor: 2.062

View more
  4 in total

1.  Lack of association of CYP11B2-344C/T polymorphism with essential hypertension: a meta-analysis.

Authors:  Jian-Fei Chen; Jun Jing; Hu Tan; Min-Bao Song; Shi-Yong Yu; Lan Huang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms.

Authors:  Worapaka Manosroi; Gordon H Williams
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

3.  Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.

Authors:  Alberto Galizzi; Mara Bagardi; Angelica Stranieri; Anna Maria Zanaboni; Dario Malchiodi; Vitaliano Borromeo; Paola Giuseppina Brambilla; Chiara Locatelli
Journal:  BMC Vet Res       Date:  2021-01-07       Impact factor: 2.741

4.  Relationship of Genetic Polymorphisms of Aldosterone Synthase Gene Cytochrome P450 11B2 and Mineralocorticoid Receptors with Coronary Artery Disease in Taiwan.

Authors:  Chi-Hung Chou; Kwo-Chang Ueng; Shun-Fa Yang; Chih-Hsien Wu; Po-Hui Wang
Journal:  Int J Med Sci       Date:  2016-02-01       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.